Francisco Silva - Nov 19, 2021 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role: VP of Research and Development, Director
Signature: /s/ Francisco Silva
Stock symbol: BRTX
Transactions as of: Nov 19, 2021
Transactions value $: $26,626
Form type: 4
Date filed: 11/22/2021, 11:17 AM
Previous filing: Nov 16, 2021
Next filing: Mar 22, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BRTX	Common Stock	Purchase	$26.6K	+4K	+51.09%	$6.66	11.8K	Nov 19, 2021	IRA	F2
holding	BRTX	Common Stock						149K	Nov 19, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BRTX	Stock Option						1	Nov 19, 2021	Common Stock	1	$3,000.00	Direct	F3
holding	BRTX	Stock Option						1	Nov 19, 2021	Common Stock	1	$3,000.00	Direct	F3
holding	BRTX	Stock Option						1	Nov 19, 2021	Common Stock	1	$3,000.00	Direct	F3
holding	BRTX	Stock Option						1	Nov 19, 2021	Common Stock	1	$3,000.00	Direct	F3
holding	BRTX	Stock Option						3	Nov 19, 2021	Common Stock	3	$3,000.00	Direct	F3
holding	BRTX	Stock Option						1	Nov 19, 2021	Common Stock	1	$3,000.00	Direct
holding	BRTX	Stock Option						1	Nov 19, 2021	Common Stock	1	$3,000.00	Direct
holding	BRTX	Stock Option						9	Nov 19, 2021	Common Stock	9	$3,000.00	Direct	F3
holding	BRTX	Stock Option						6	Nov 19, 2021	Common Stock	6	$3,000.00	Direct	F3
holding	BRTX	Stock Option						15	Nov 19, 2021	Common Stock	15	$3,000.00	Direct	F3
holding	BRTX	Stock Option						20	Nov 19, 2021	Common Stock	20	$3,000.00	Direct	F3
holding	BRTX	Stock Option						25	Nov 19, 2021	Common Stock	25	$3,000.00	Direct	F3
holding	BRTX	Stock Option						293K	Nov 19, 2021	Common Stock	293K	$13.50	Direct	F4
holding	BRTX	Stock Option						42.1K	Nov 19, 2021	Common Stock	42.1K	$13.50	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024.
F2	The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.605 to $6.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
F3	The option is currently exercisable.
F4	The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F5	The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.